



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/505</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/44039</b> <b>(43) International Publication Date:</b> 27 November 1997 (27.11.97)
<b>(21) International Application Number:</b> PCT/EP97/02504 <b>(22) International Filing Date:</b> 12 May 1997 (12.05.97) <b>(30) Priority Data:</b> 96201429.6 20 May 1996 (20.05.96) EP <b>(34) Countries for which the regional or international application was filed:</b> DE et al.  <b>(71) Applicant (for all designated States except US):</b> JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FRANÇOIS, Marc, Karel, Jozef [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). EMBRECHTS, Roger, Carolus, Augusta [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). BORGHIJS, Herman, Karel [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). MONBALIU, Johan [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).		<b>(81) Designated States:</b> AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS  <b>(57) Abstract</b>  The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxyrisperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and (2) a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein; and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## AQUEOUS SUSPENSIONS OF 9-HYDROXYRISPERIDONE FATTY ACID ESTERS

---

- 5 The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising :
- (1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof and
- 10 (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein ;
- and with a process of preparing such a composition. The invention further involves such a pharmaceutical composition for use as a medicament in the treatment of
- 15 schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.

Risperidone is generic to 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. The preparation and pharmacological activity thereof are described in EP-0,196,132 (corresponding to US-4,804,663). Various conventional pharmaceutical dosage forms, including tablets, capsules, drops, suppositories, oral solutions and injectable solutions are exemplified therein. In practice, risperidone is normally administered as the base in a tablet or in a

20 buffered, oral or intramuscular solution. Particular solutions for oral or intramuscular administration are described in WO-96/01652.

Risperidone is a highly potent drug having a relatively narrow therapeutic index. It may produce undesirable side effects on overdosage, most notably extra pyramidal syndrome (EPS) and to a lesser extent hypotension (due to peripheral alpha-adrenergic activity). For the purpose of producing an antipsychotic effect in a patient the total

30 daily dose of risperidone ranges from about 2 to about 8 mg ; for the alleviation of behavioral disturbances associated with neurodegenerative disorders the total daily dose is usually less and typically ranges from about 0.5 to about 2 mg. Inter-individual

35 differences and co-medication may necessitate dose titrating in patients.

For a number of reasons, it is desirable to administer risperidone in a sustained or delayed release (depot) formulation which is effective over an extended period of time,

preferably about 3 weeks or more.

WO-94/25460 (corresponding to EP-0,697,019) relates to a first such depot formulation and concerns the risperidone pamoate salt, a poorly water-soluble salt form of risperidone, which may be suspended in a pharmaceutically acceptable carrier, such as water or an oil, and may be administered subcutaneously or intramuscularly. This salt, however, has pharmacokinetic properties which are suboptimal. The release of the active ingredient from the formulations appears to be too rapid, which results in relatively high initial plasma levels and an inadequate mean duration of action, both characteristics which should be improved upon in a truly effective depot formulation.

WO-95/13814 concerns sustained release formulations for parenteral administration wherein risperidone is microencapsulated in a biocompatible, biodegradable wall-forming material (e.g. a polymer such as dl-(polylactide-co-glycolide)). The microencapsulated formulations have suitable pharmacokinetic properties, but require sophisticated processes of preparation in a purpose-built plant.

Consequently, there is still a need for an effective and readily available depot formulation of risperidone or a risperidone-like compound.

It is known that risperidone is metabolized to 9-hydroxyrisperidone which has a pharmacological profile and potency comparable with that of the parent drug risperidone, but which has a longer elimination half-life. Risperidone is distributed to and eliminated from the brain tissues more rapidly than its metabolite 9-hydroxyrisperidone. 9-hydroxyrisperidone, its enantiomeric forms and the C<sub>2</sub>-20 alkanolic acid esters thereof are described in EP-0,368,388 (corresponding to US-5,158,952 and US-5,254,556). Said esters are considered to be potentially valuable prodrugs of the active metabolite of risperidone for use in depot formulations.

In addition, the problems associated with the genetic polymorphism in the metabolism of risperidone to its active metabolite 9-hydroxyrisperidone can possibly be avoided by administration of the metabolite or a long-acting prodrug thereof, instead of risperidone itself.

Indeed, in the metabolism of risperidone, debrisoquine-type genetic polymorphism plays a distinct role. As a consequence, humans can be phenotyped as poor, intermediate or extensive metabolizers on the basis of their metabolic ratio. Said metabolic ratio is defined as the ratio of urine recovery of debrisoquine to that of the 4-hydroxymetabolite of debrisoquine over a period of 8 hours after an oral intake of

10 mg debrisoquine. In oriental people more than 99% of the population can be phenotyped as extensive metabolizers and poor metabolizers are rather seldom. In the Caucasian race however only about 90% of the population can be phenotyped as either extensive or intermediate metabolizers. Approximately 10% of the population are poor  
5 metabolizers and have deficient amounts of the debrisoquine-hydroxylase enzyme.

The duration of action and the peak plasma levels of active agents (risperidone and 9-hydroxyrisperidone) are dependent on the debrisoquine metabolic ratio of the human subject treated with risperidone. More in particular, in poor metabolizers high transient  
10 peak levels of risperidone are likely to be attained when the total daily amount is administered in a single dose. This may give rise to undesired side-effects such as extra pyramidal syndrome (EPS) and hypotension.

Further inter-individual differences among humans, as far as the metabolism of  
15 risperidone is concerned, are due to the fact that in clinical practice the human subjects to be treated with risperidone will usually receive additional medication, e.g. tranquillizers such as phenothiazines, neuroleptics such as haloperidol, antidepressiva etc., all of which may compete with risperidone for the debrisoquine-hydroxylase enzyme. These drug interactions may seriously affect the metabolism of risperidone,  
20 especially in extensive metabolizers, and may result in the occurrence of adverse effects in patients receiving such additional medication.


The present invention results from the investigations into the development of an efficient, well-tolerated, sustained or delayed release (depot) formulation of a  
25 9-hydroxyrisperidone alkanoic acid ester which is therapeutically effective for at least three weeks or more. By the expression "effective for at least three weeks or more", one means that the plasma levels of the active ingredient, 9-hydroxyrisperidone (free alcohol liberated by hydrolysis from the alkanoic acid ester), should be above approximately 10 ng/ml. On the other hand, said plasma levels should remain at all  
30 times below a threshold value of approximately 100 ng/ml in order for one to call the formulation "efficient". The threshold value is the mean plasma level during a considerable period of time, e.g. for more than 15 minutes, above which patients may experience undesirable side effects, or conversely, the value of the plasma level under which the systemic tolerance of the formulation in question is still acceptable. The  
35 threshold value does not hold for transient, high plasma levels during a short period of time, e.g. for less than 15 minutes, which are due, for example to unexpected burst-release of the active ingredient.

Both of the foregoing features - plasma levels above a minimal therapeutical concentration but below a side-effect producing threshold value - are considered to be basic requirements that a contemporary depot formulation should fulfil in order to be acceptable for the intended patients. Limiting the number of drug administrations and the occurrence of undesirable side effects after each administration will undoubtedly improve the patients' compliance with the therapy. However, beyond these basic requirements, a number of further desiderata can be identified which would further improve patients' compliance ; the two most notable being good local tolerance and ease of administration.

Good local tolerance means minimal irritation and inflammation at the site of injection; ease of administration refers to the size of needle and length of time required to administer a dose of a particular drug formulation. In addition, depot formulations should be stable and have a shelf-life of at least two years under normal conditions.

The investigations into the development of an efficient, well-tolerated, sustained or delayed release (depot) formulation of a 9-hydroxyrisperidone alkanoic acid ester which fulfils the above mentioned requirements, led to the finding that a pharmaceutical composition suitable as a depot formulation for administration by intramuscular or subcutaneous injection should comprise :

- (1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester having the formula



- or a salt, or a stereoisomer or a stereoisomeric mixture thereof, wherein R represents a straight C<sub>9-19</sub>alkyl radical ; and
- (2) a pharmaceutically acceptable carrier; characterized in that the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein.



Surprisingly, it appears that aqueous suspensions of 9-hydroxyrisperidone C<sub>10-20</sub> alkanolic acid esters (wherein R represents a straight C<sub>9-19</sub> alkyl radical) are comparable and in some respects far better depot formulations than corresponding suspensions in non-aqueous, oily suspensions. This is quite unexpected since it is somewhat of a tenet in the art that depot formulations must comprise lipophilic drugs dissolved or suspended in a lipophilic medium. Hitherto, the 9-hydroxyrisperidone C<sub>10-20</sub> alkanolic acid esters were therefore formulated in oils suitable for intramuscular administration, in particular in sesame oil. C<sub>10-20</sub> alkanolic acids are selected from the group consisting of decanoic (capric), undecanoic, dodecanoic (lauric), tridecanoic, tetradecanoic (myristic), pentadecanoic, hexadecanoic (palmitic), heptadecanoic, octadecanoic (stearic), nonadecanoic and eicosanoic acid. Due to their limited aqueous solubility, it was generally believed that the esters had to be suspended into oils. The ester having a C<sub>15</sub> (pentadecyl) chain and the active ingredient corresponding thereto being the 9-hydroxyrisperidone palmitate ester was found to be the superior ester from a pharmacokinetic, as well as from a tolerance point of view.

In order to improve the tolerance further, several suspensions with different size particles of 9-hydroxyrisperidone palmitate ester in sesame oil, optionally in the presence of aluminum monostearate, were next considered. No significant difference between small or large prodrug particles could be established. The presence of the aluminum monostearate only affected the viscosity of the formulation and its ease of administration. In yet another set of experiments, it was found that upon decreasing the prodrug concentration in the depot formulation, the tolerance to the administered formulation improved still further. Because the oil suspensions proved difficult to take up in a syringe, experiments with less viscous carriers were initiated, in particular with a medium-chain triglyceride (Miglyol™), and contrary to what the tenet holds, with water as a carrier. The Miglyol™ formulations exhibited considerably less systemic and local tolerance than the sesame oil based formulations. To our big surprise, however, the aqueous suspensions of the 9-hydroxyrisperidone palmitate ester outperformed the sesame oil based formulations. They have not only an appropriate duration of action, but also acceptable systemic and local tolerance, and a strikingly limited inter-individual variability of pharmacokinetic properties.

The pharmacokinetic properties of the aqueous suspensions according to the present invention further may depend to a limited extent on the physico-chemical properties of the 9-hydroxyrisperidone palmitate ester solid, such as the particle size and crystal form.

Aqueous compositions according to the present invention conveniently further comprise a suspending agent and a wetting agent, and optionally one or more of a preservative, a buffer and an isotonicizing agent. Particular ingredients may function as two or more of these agents simultaneously, e.g. behave like a preservative and a  
5 buffer, or behave like a buffer and an isotonicizing agent.

Suitable suspending agents for use in the aqueous suspensions according to the present invention are cellulose derivatives, e.g. methyl cellulose, sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose, polyvinylpyrrolidone, alginates,  
10 chitosan, dextrans, gelatin, polyethylene glycols, polyoxyethylene- and polyoxypropylene ethers. Preferably sodium carboxymethyl cellulose is used in a concentration of 0.5 to 2%, most preferably 1% (w/v). Suitable wetting agents for use in the aqueous suspensions according to the present invention are polyoxyethylene derivatives of sorbitan esters, e.g. polysorbate 20 and polysorbate 80, lecithin, polyoxyethylene- and  
15 polyoxypropylene ethers, sodium deoxycholate. Preferably polysorbate 20 is used in a concentration of 0.05 to 0.3%, more preferably 0.05 to 0.2 %, most preferably 0.1 % (w/v).

Preservatives are antimicrobials and anti-oxidants which can be selected from the group  
20 consisting of benzoic acid, benzyl alcohol, butylated hydroxyanisole, butylated hydroxytoluene, chlorbutol, a gallate, a hydroxybenzoate, EDTA, phenol, chlorocresol, metacresol, benzethonium chloride, myristyl- $\gamma$ -piccolinium chloride, phenylmercuric acetate and thimerosal. In particular, it is benzyl alcohol which can be used in a concentration up to 2% (w/v), preferably up to 1.5% (w/v). Isotonicizing agents are, for  
25 example, sodium chloride, dextrose, mannitol, sorbitol, lactose, sodium sulfate. The suspensions conveniently comprise from 1 to 10 % (w/v) isotonicizing agent. Preferably, mannitol is used in a concentration from 2 to 7%, more preferably about 5%. Most preferably, however, from about 1 to about 3 % (w/v), especially from about 1.5 to about 2 % (w/v) of one or more electrolytes are used to render the suspension isotonic,  
30 apparently because ions help to prevent flocculation of the suspended ester. In addition, particular electrolytes have the further advantage of buffering the aqueous suspension. Particularly preferred is the use of a mixture of disodium hydrogen phosphate (anhydrous) (typically about 0.9 % (w/v)) and sodium dihydrogen phosphate monohydrate (typically about 0.6 % (w/v)) for rendering the solution isotonic, neutral  
35 and less prone to flocculation of the suspended ester therein.

A particularly desirable feature for an injectable depot formulation relates to the ease with which it can be administered. In particular such an injection should be feasible



using a needle as fine as possible in a span of time which is as short as possible. This can be accomplished with the aqueous suspensions of the present invention by keeping the viscosity below about 75 mPa.s, preferably below 60 mPa.s. Aqueous suspensions of such viscosity or lower can both easily be taken up in a syringe (e.g. from a vial),  
5 and injected through a fine needle (e.g. a 21 G 1 1/2, 22 G 2 or 22 G 1 1/4 needle).

Ideally, aqueous suspensions according to the present invention will comprise as much prodrug as can be tolerated so as to keep the injected volume to a minimum, and as little of the other ingredients as possible. In particular, such a composition will  
10 comprise by weight based on the total volume of the composition :

- (a) from 3 to 20 % (w/v) of the prodrug;
- (b) from 0.05 to 0.2 % (w/v) of a wetting agent;
- (c) from 0.5 to 2 % (w/v) of a suspending agent;
- (d) up to 2 % (w/v) preservatives;
- 15 (e) optionally one or more isotonicizing agents sufficient to render the composition isotonic with serum; and
- (f) water *q.s. ad* 100%.

The aqueous suspensions according to the present invention can be prepared following  
20 art-known processes of preparing suspensions characterized by intimately mixing the active ingredient with the carrier.

Such a process may comprise the steps of :

- (a) stirring the wetting agent with the water;
- 25 (b) adding the preservative to the mixture while stirring;
- (c) dispersing the suspending agent in the mixture while stirring;
- (d) optionally dissolving the isotonicizing agent in the mixture while stirring;
- (e) dispersing the active ingredient in the mixture while stirring, followed by  
homogenizing the mixture.

30 In view of the usefulness of 9-hydroxyrisperidone in the treatment of a number of disorders, the present invention also concerns a pharmaceutical composition as described hereinbefore for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative  
35 disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.

In addition, the present invention concerns the use of a composition as described hereinbefore for the preparation of a medicament for treating schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.

The present invention further concerns a method of treating warm-blooded animals, in particular humans suffering from schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety, said method comprising the administration of a therapeutically effective amount of an aqueous suspension as described hereinbefore. Typically, said formulation will be administered approximately every three weeks or even at longer intervals where possible. The dosage should range from about 2 to 4 mg/kg body weight.

The following examples are intended to illustrate the present invention.

#### Experimental Part

##### A. Preparation of 9-hydroxyrisperidone palmitate ester.

*N,N*-Dicyclohexylcarbodiimide (1.39 g ; 6.8 mmol) was added to a solution of hexadecanoic acid (1.54 g ; 6 mmol) in dichloromethane (140 ml) and stirred at room temperature for 10 minutes. 9-hydroxyrisperidone (2.13 g ; 5 mmol) was added to the reaction mixture, followed by 4-pyrrolidinopyridine (93 mg ; 0.63 mmol). The mixture was stirred for three days at room temperature. Water (200 ml) was added to the reaction mixture and this was extracted three times with chloroform (100 ml). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and evaporated. The mixture was triturated in diisopropylether (100 ml), filtered and recrystallized in isopropanol (60 ml). The crystals were filtered off and dried, yielding 9-hydroxyrisperidone palmitate ester (2.67g; 80.4%).

##### B. Composition examples.

Each of the formulations hereunder was prepared according to the following general recipe :

The wetting agent was stirred with the water at room temperature and the preservative was added thereto. While stirring, the suspending agent was dispersed in the mixture, and the isotonicizing agent - if any - was added. Next, the active ingredient was dispersed into the stirred mixture which was then homogenized and filled into sterile

containers. All ingredients and apparatus used during the preparation of the aqueous suspensions were sterile. In the tables hereunder, all concentrations are expressed as % weight by volume of the total formulation [% (w/v)].

5 Formulation 1 (F1)

	9-hydroxyrisperidone palmitate *	15.6 % (10 % 9-hydroxyrisperidone)
	poly sorbate 20	0.2 %
	sodium carboxymethyl cellulose 30 mPa.s	2 %
	benzyl alcohol	1.5 %
10	water <i>q.s. ad</i>	100 %

\* The ester was milled, but not sieved.

Physico-chemical properties of F1

pH = 6.52

15 viscosity = 20 mPa.s

osmolality =  $\pm$  210 mOsm/kg

Formulation 2a, 2b and 2c (F2a, F2b, F2c)

	9-hydroxyrisperidone palmitate #	7.8 % (5 % 9-hydroxyrisperidone)
20	polysorbate 20	0.1 %
	sodium carboxymethyl cellulose 30 mPa.s	2 %
	benzyl alcohol	1.5 %
	mannitol	2 %
25	water <i>q.s. ad</i>	100 %

# The ester was milled and sieved into three fractions :

F2a (particle size < 10  $\mu$ m) viscosity = 19 mPa.s

F2b (10  $\mu$ m < particle size < 30  $\mu$ m) viscosity = 29 mPa.s

30 F2c (particle size > 30  $\mu$ m) viscosity = 32 mPa.s

pH = 6.86

osmolality =  $\pm$  280 mOsm/kg

Formulation 3a, 3b and 3c (F3a, F3b, F3c)

35	9-hydroxyrisperidone palmitate #	15.6 % (10 % 9-hydroxyrisperidone)
	polysorbate 20	0.2 %
	sodium carboxymethyl cellulose 30 mPa.s	1 %
	benzyl alcohol	1.5 %

mannitol	2 %
water q.s. ad	100 %

# The ester was milled and sieved into three fractions :

5	F3a (particle size < 10 $\mu\text{m}$ )	viscosity = $\pm 60$ mPa.s
	F3b (10 $\mu\text{m}$ < particle size < 30 $\mu\text{m}$ )	viscosity = $\pm 60$ mPa.s
	F3c (particle size > 30 $\mu\text{m}$ )	viscosity = $\pm 60$ mPa.s

pH = 6.74

10 osmolality =  $\pm 280$  mOsm/kg

#### Formulation 4 (F4)

	9-hydroxyrisperidone palmitate #	7.8 % (5 % 9-hydroxyrisperidone)
	polysorbate 20	0.2 %
15	sodium carboxymethyl cellulose 30 mPa.s	1 %
	benzyl alcohol parenteral	1.5 %
	disodium hydrogen phosphate anhydrous	0.9 %
	sodium dihydrogen phosphate monohydrate	0.6 %
20	water q.s. ad	100 %

# The ester was milled and sieved using appropriate nominal standard test sieves, yielding active ingredient having a particle size distribution as follows :

90 % of the particles (by volume)  $\geq 0.5$   $\mu\text{m}$

50 % of the particles (by volume)  $\geq 5$   $\mu\text{m}$

25 10 % of the particles (by volume)  $\geq 15$   $\mu\text{m}$ .

The ester was sterilized by irradiation with 25 kGy  $^{60}\text{Co}$  and mixed with the solvent (filtered through a 0.22  $\mu\text{m}$  membrane filter and autoclaved during 30 minutes at 121  $^{\circ}\text{C}$ ) under sterile conditions.

30 pH = 7

viscosity =  $\pm 10$  mPa.s

osmolality =  $\pm 450$  mOsm/kg

The syringeability through a 22 G 1  $\frac{1}{4}$  needle posed no problem.

Formula 5a, 5b and 5c (F5a, F5b, F5c)

	F5a	F5b	F5c
9-hydroxyrisperidone palmitate #	15.6 %	23.4 %	31.2 %
polysorbate 20	0.2 %	0.2 %	0.3 %
5 sodium carboxymethyl cellulose 30 mPa.s	1 %	1 %	0.5 %
benzyl alcohol parenteral	1.5 %	1.5 %	1.5 %
disodium hydrogen phosphate anhydrous	0.9 %	0.9 %	0.9 %
sodium dihydrogen phosphate monohydrate	0.6 %	0.6 %	0.6 %
water q.s. ad	100 %	100 %	100 %
10 pH	7	7	7
viscosity (mPa.s)	12	16	16
osmolality (mOsm)/kg	± 450	± 450	± 450
15 The syringeability through a 22 G 1 ¼ needle	OK	OK	OK


C. Pharmacological examples.C.1. Pharmacological testing of F1 and analogous oil formulations.

F1 was administered intramuscularly at 2.5 mg/kg bodyweight to four beagle dogs using a 21 G needle. In the same experiment, a similar formulation based on Miglyol™ (Fα) and one based on sesame oil (Fβ) were used, as well as a suspension comprising 9-hydroxyrisperidone decanoate in sesame oil (Fγ). The Miglyol™ formulation was also administered using a 21 G needle, but both sesame oil based formulations had to be administered using a 19 G needle. The following pharmacokinetic parameters were calculated from the experimental data :

	C <sub>max</sub> (ng/ml)	T <sub>max</sub> (h)	AUC <sub>0-672h</sub> (ng.h/ml)	C <sub>av</sub> (ng/ml)	C <sub>672h</sub> (ng/ml)
25 F1	54.6 (± 7.3)	276 (± 80)	18210 (± 1350)	27.1	8.8 (± 4.7)
30 Fα	86.5 (± 33.2)	234 (± 82)	22082 (± 6319)	32.9	2.5 (≤ 2.0-7.8)
Fβ	21.9 (± 9.4)	210 (± 84)	7054 (± 3489)	10.5	4.2 (≤ 2.0-6.5)
Fγ	33.1 (± 18.2)	132 (± 42)	13875 (± 6208)	20.6	12.0 (± 5.6)

Claims

1. A pharmaceutical composition suitable as a depot formulation for administration by intramuscular or subcutaneous injection, comprising :
- 5 (1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester having the formula



- 10 or a salt, or a stereoisomer or a stereoisomeric mixture thereof, wherein R represents a straight C<sub>9-19</sub>alkyl radical ; and
- (2) a pharmaceutically acceptable carrier; characterized in that the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein.
- 15 2. A composition according to claim 1 wherein R represents a straight C<sub>15</sub> (pentadecyl) chain and the active ingredient is 9-hydroxyrisperidone palmitate ester.
- 20 3. A composition according to claim 1 wherein the composition further comprises a suspending agent and a wetting agent, and optionally one or more of a preservative, a buffer and an isotonicizing agent.
- 25 4. A composition according to claim 3 wherein the suspending agent is sodium carboxymethyl cellulose and the wetting agent is polysorbate 20.
5. A composition according to claim 4 wherein the preservative is benzyl alcohol and the isotonicizing agent is mannitol or a phosphate buffer.
- 30 6. A composition according to claim 1 having a viscosity of less than 75 mPa.s.



7. A composition according to claim 1 comprising by weight based on the total volume of the composition :
- (a) from 3 to 20 % (w/v) of the prodrug;
  - 5 (b) from 0.05 to 0.2 % (w/v) of a wetting agent;
  - (c) from 0.5 to 2 % (w/v) of a suspending agent;
  - (d) up to 2 % (w/v) preservatives;
  - (e) optionally one or more isotonizing agents sufficient to render the composition isotonic with serum; and
  - 10 (f) water *q.s. ad* 100%.
8. A process of preparing a pharmaceutical composition as claimed in any one of claims 1 to 7, characterized by intimately mixing the active ingredient with the carrier.
- 15 9. A process according to claim 8 comprising the steps of :
- (a) stirring the wetting agent with the water;
  - (b) adding the preservative to the mixture while stirring;
  - (c) dispersing the suspending agent in the mixture while stirring;
  - 20 (d) optionally dissolving the isotonizing agent in the mixture while stirring;
  - (e) dispersing the active ingredient in the mixture while stirring, followed by homogenizing the mixture.
- 25 10. A pharmaceutical composition as claimed in any one of claims 1 to 7 for use as a medicament in the treatment of schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
- 30 11. The use of a composition as claimed in any one of claims 1 to 7 for the preparation of a medicament for treating schizophrenia, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, bipolar mania, depression, anxiety.
- 35

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/02504

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 96 39397 A (HOECHST MARION ROUSSEL) 12 December 1996 see page 7 - page 9 see page 24 - page 25 ---	1-11
A	EP 0 368 388 A (JANSSEN PHARMACEUTICA) 16 May 1990 cited in the application -----	

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the international search

4 September 1997

Date of mailing of the international search report

19.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Klaver, T

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/02504

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9639397 A	12-12-96	AU 5746496 A	24-12-96
		AU 5867796 A	24-12-96
		WO 9639405 A	12-12-96
-----			
EP 368388 A	16-05-90	AT 122349 T	15-05-95
		AU 614437 B	29-08-91
		AU 4443689 A	10-05-90
		CA 2000786 A	07-05-90
		DE 68922577 D	14-06-95
		DE 68922577 T	28-09-95
		DK 169923 B	03-04-95
		ES 2075036 T	01-10-95
		FI 92201 B	30-06-94
		HK 131696 A	26-07-96
		IE 66370 B	27-12-95
		JP 2191276 A	27-07-90
		PT 92206 B	06-07-95
		US 5158952 A	27-10-92
		US 5254556 A	19-10-93
-----			

**THIS PAGE BLANK (USPTO)**